Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EGRX Eagle Pharmaceuticals	$3.20	$3.11	$1.50 ▼ $3.87	$41.56M	0.83	7,182 shs	N/A
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
RENB Renovaro	$0.24 -0.5%	$0.30	$0.22 ▼ $2.10	$40.79M	0.54	2.17 million shs	736,901 shs
XCUR Exicure	$6.87 +3.2%	$7.36	$1.44 ▼ $36.00	$43.39M	3.67	77,395 shs	6,179 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EGRX Eagle Pharmaceuticals	0.00%	+0.31%	-13.51%	+64.95%	-29.36%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
RENB Renovaro	0.00%	-2.96%	-24.55%	-24.29%	-64.75%
XCUR Exicure	0.00%	-10.74%	-16.14%	-35.00%	+1,747.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	1.7123 of 5 stars	0.0	5.0	0.0	0.0	2.8	1.7	0.6
XCUR Exicure	2.1972 of 5 stars	0.0	5.0	0.0	4.7	3.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EGRX Eagle Pharmaceuticals	$257.55M	0.16	$8.00 per share	0.40	N/A	∞
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	$0.89 per share	N/A
XCUR Exicure	$500K	86.77	N/A	N/A	$1.12 per share	6.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	-$88.43M	-$0.77	N/A	∞	N/A	N/A	-60.38%	-47.04%	9/29/2025 (Estimated)
XCUR Exicure	-$9.70M	-$3.88	N/A	∞	N/A	N/A	-192.16%	-84.30%	N/A

Latest PHXM, XCUR, EGRX, and RENB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/8/2025	Q2 2025	XCUR Exicure	N/A	-$0.41	N/A	-$0.41	N/A	N/A
6/27/2025	Q1 2025	XCUR Exicure	N/A	-$0.45	N/A	$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
RENB Renovaro	N/A	0.13	0.13
XCUR Exicure	N/A	1.89	1.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EGRX Eagle Pharmaceuticals	85.36%
PHXM PHAXIAM Therapeutics	0.40%
RENB Renovaro	71.41%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
EGRX Eagle Pharmaceuticals	28.90%
PHXM PHAXIAM Therapeutics	1.94%
RENB Renovaro	0.50%
XCUR Exicure	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
RENB Renovaro	20	172.12 million	171.26 million	Optionable
XCUR Exicure	50	6.32 million	5.79 million	Not Optionable

PHXM, XCUR, EGRX, and RENB Headlines

Recent News About These Companies

Short Interest in Exicure, Inc. (NASDAQ:XCUR) Drops By 51.8%

August 18 at 2:15 AM | americanbankingnews.com

Exicure Posts Wider Loss in Fiscal Q2

August 8, 2025 | aol.comA

Exicure, Inc. Reports Second Quarter 2025 Financial Results | XCUR Stock News

August 8, 2025 | gurufocus.com

Exicure, Inc. Reports Second Quarter 2025 Financial Results

August 8, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

August 4, 2025 | businesswire.com

Stocks to Watch: Exicure, TTEC

August 3, 2025 | marketwatch.com

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

August 1, 2025 | businesswire.com

XCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatch

July 19, 2025 | marketwatch.com

Is Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?

June 30, 2025 | msn.com

Exicure Shares Up After Swing to Profit in 1Q

June 27, 2025 | marketwatch.com

Exicure, Inc. Reports First Quarter 2025 Financial Results

June 27, 2025 | businesswire.com

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025 | businesswire.com

Why Exicure Inc. (XCUR) Soared on Monday

April 22, 2025 | msn.com

Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma

April 16, 2025 | pharmabiz.comP

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100

April 15, 2025 | pharmabiz.comP

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

April 14, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...

April 11, 2025 | gurufocus.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | investing.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | businesswire.com

Wednesday’s Insider Moves: Top Buys and Sells in US Stocks

March 27, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM, XCUR, EGRX, and RENB Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

$3.20 0.00 (0.00%)

As of 08/15/2025

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/15/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Renovaro NASDAQ:RENB

$0.24 0.00 (-0.46%)

As of 02:56 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Exicure NASDAQ:XCUR

$6.86 +0.22 (+3.23%)

As of 02:57 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time